Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML.

International journal of molecular sciences - 24 Feb 2020

Lam Stephen S Y, Leung Anskar Y H

Abstract excerpt

Acute myeloid leukaemia (AML) carrying internal tandem duplication (ITD) of Fms-Like Tyrosine kinase 3 (FLT3) gene is associated with high risk of relapse and poor clinical outcome upon treatment with conventional chemotherapy. FLT3 inhibitors have been approved for the treatment of this AML subtype but leukaemia relapse remains to be a major cause of treatment failure. Mechanisms of drug resistance have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Staurosporine

Source

Open in PubMed Open full text

Identifiers

PMID: 32102366
DOI: 10.3390/ijms21041537
PMCID: PMC7073218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML.PMID 32102366Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Semantic proximity Read ↗

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategiesSemantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

The Future of Targeting FLT3 Activation in AML.Semantic proximity Read ↗

Targeting FLT3 to treat leukemia.Semantic proximity Read ↗

Can FLT3 inhibitors overcome resistance in AML?Semantic proximity Read ↗

Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity Read ↗

Developments and challenges of FLT3 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Drug resistance in mutant FLT3-positive AML.Semantic proximity Read ↗

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.